ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31
ADC Therapeutics SA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.44+0.04 (+2.86%)
Close on Oct 19, 2026
- Market cap
- $223.22M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
92.9%
Operating margin
-149.3%
Net margin
-175.3%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +14.9% | -27.1% | – | – | |
| Gross profit | +16.4% | -28.5% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 73.4% | |
| Return on assets | – | -75.6% | -44.2% | |
| Current ratio | – | 11.14 | 4.37 | |
| Interest coverage | – | -44.5× | -2.4× | |
| Inventory turnover | – | – | 1.8× | |
| Capex to revenue | – | – | 0.3% | |
| Diluted shares | – | 65M | 127M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ADC Therapeutics generated $755.38M from operations and spent $8.46M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$755.38M
Used
$8.46M
Capital expenditure$8.46M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-175.3%
×Asset turnover0.25×
×Equity multiplier-1.66×
=Return on equity, FY202573.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -175.3% | 0.25× | -1.66× | 73.4% |
| FY2024 | -222.8% | 0.21× | -1.93× | 90.0% |
| FY2023 | -345.1% | 0.16× | -12.29× | 697.8% |
| FY2022 | -74.9% | 0.38× | 4.75× | -134.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$142.62M
- Cash generatingOperating cash flow above zero-$141.17M
- Return on assets improvedROA up on the prior year-44.5% → -44.3%
- Earnings backed by cashOperating cash flow above net income-$141.17M vs -$142.62M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.62 → 4.37
- No dilutionShare count did not rise97M → 127M
- Gross margin improvedGross margin up on the prior year91.60% → 92.87%
- More efficientAsset turnover rose0.20 → 0.25